Follow-The-Filings

Security · featured owners

SNDX

Syndax Pharmaceuticals Inc. COM Equity as of 2026 Q2 among managers we track

  • 3 Owners
  • Max 3.1%
  • $30M
  • 3 add 1 exit

Who owns this now

Largest portfolio weights among featured holders · max 3.1% (Palo Alto Investors) · not free-float ownership

  1. Palo Alto Investors add 3.1%
  2. Nathan Fischel add 1.4%
  3. Torray Investment Partners add 0.4%

holders

sorted by % of portfolio · long equity only · exits show last held size · open a manager for their book

history
Palo Alto Investors 2026 Q1 stale 3.1% Add +8.9% 864,986 $20M hist
Nathan Fischel - Dafna Capital Management 2026 Q2 1.4% Add +54.2% 335,255 $7M hist
Torray Investment Partners 2026 Q2 0.4% Add +27.6% 133,835 $3M hist
Farallon Capital Management exited 2026 Q2 last 2026 Q1 0% Exit 0.00 pp 10,000 $234K hist

3 current · 1 exited last period · options excluded

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $0.00 $23.68M $172.35M
Gross profit — — —
Gross margin — — —
Net income -$209.36M -$318.76M -$285.42M
Net margin * — -1346.1% -165.6%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $580.88M $603.06M $528.08M
Total non-current assets * $32M $121.76M $1.62M
Total assets $612.88M $724.82M $529.71M
Total current liabilities $58.1M $103.55M $120.12M
Total non-current liabilities $588,000 $333.14M $344.96M
Total equity $554.2M $288.12M $64.63M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$160.6M -$274.9M -$322.98M
Cash from investing $117.61M -$219.78M $290.04M
Cash from financing $264.13M $353.37M $13.68M
Net change in cash $221.14M -$141.31M -$19.27M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders